ANTECIP EXHIBIT 2023
`Grunenthal GmbH v. Antecip Bioventures II LLC
`PGR2017-00022
`
`Page 1
`
`

`

`US 9,283,239 B2
`
`Page 2
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`2011/0098252 A1
`2012/0190647 A1
`2013/0274282 A1
`2013/0303485 A1
`2013/0303486 A1
`2013/0303487 A1
`2013/0303488 A1
`2014/0051669 A1
`2014/0051718 A1
`2014/0249107 A1
`2014/0249108 A1
`2014/0249109 A1
`2014/0249111 A1
`2014/0249112 A1
`2014/0249113 A1
`2014/0249317 A1
`
`4/2011 Pappagallo
`7/2012 Hanna et al.
`10/2013 Tabuteau
`11/2013 Tabuteau
`11/2013 Tabuteau
`11/2013 Tabuteau
`11/2013 Tabuteau
`2/2014 Tabuteau
`2/2014 Tabuteau
`9/2014 Tabuteau
`9/2014 Tabuteau
`9/2014 Tabuteau
`9/2014 Tabuteau
`9/2014 Tabuteau
`9/2014 Tabuteau
`9/2014 Tabuteau
`
`FOREIGN PATENT DOCUMENTS
`
`WO
`WO
`WO
`
`2005063218
`2005/107751 A1
`2012071517
`
`7/2005
`11/2005
`5/2012
`
`U.S. Appl. No. 14/635,857, filed Mar. 2, 2015 First Named Inventor:
`Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`U.S.Appl. No. 14/639,013, filed Mar. 13,2015 First Named Inventor:
`Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`ISR & Written Opinion for PCT/US2014/050427, mailed Nov. 20,
`2014.
`Adami, S. et al., “Bispho sphonate therapy of reflex sympathetic
`dystrophy syndrome”, Annals of Rheumatic Diseases, 56:201-204
`(1997).
`Allen, Ginger et al., “Epidemiology of complex regional pain syn-
`drome: a retrospective chart review of 134 patients”, Pain® 80:539-
`544 (1999).
`Alvarez-Lario, B. et al., “Acceptance of the different denominations
`for reflex sympathetic dystrophy”, Ann Rheum Dis, 60:77-79 (2001).
`Annual Mid-year Population Estimates, 2010, Office for National
`Statistics, Statistical Bulletin (2011).
`Atkins, R.M. et al., “The Use of Dolorimetry in the Assessment of
`Post-Traumatic Algodystrophy of the Hand”, British Journal of
`Rheumatology, 28:404-409 (1989).
`Azari, Pari et al., “Efficacy and Safety of Ketamine in Patients with
`Complex Regional Pain Syndrome”, CNS Drugs, 26(3):215-228
`(2012).
`ligand [Phe1(CH2i
`Bertorelli et al., Nociceptin and the ORL-l
`NH)Gly2]nociceptin(1-13)NH2 exert anti-opioid effects in the
`Freund’ s adjuvant-induced arthritic rat model ofchronic pain. British
`Journal ofPharmacology (1999) 128, 1252-1258.
`Bickerstaff, D.R. et al., “Algodystrophy: An Under-Recognized
`Complication of Minor Trauma”, British Journal of Rheumatology,
`33:240-248 (1994).
`Bickerstaff, D.R. et al., “Radiographic Changes in Algodystrophy of
`the Hand”, Journal of Hand Surgery (British Volume) 16B:47-52
`(1991).
`Bingham III et al., Risedronate decreases biochemical markers of
`cartilage degradation but does not decrease symptoms or slow radio-
`graphic progression in patients with medical
`compartment
`osteoarthritis of the knee. Arthritis & Rheumatism, vol. 54, No. 11,
`2006, 3494-3507.
`Birklein, F. MD, et al., “The important role of neuropeptides in
`complex regional pain syndrome”, Neurology, 57:2179-2184 (2001).
`Bodde, Marlies I. et al., “Therapy-Resistant Complex Regional Pain
`Syndrome Type I: To Amputate or Not?”, J. Bone Joint Surg. Am,
`93:1799-805 (2011).
`Bonabello, A. et al., “Analgesic effect of bisphosphonates in mice”,
`Pain® 91:269-275 (2001).
`Breuer, Brenda et al., “An Open-label Pilot Trial of Ibandronate for
`Complex Regional Pain Syndrome”, Clin J Pain, 24(8):685-689
`(2008).
`Bruehl, Stephen Ph.D., “An Update on the Pathophysiology of Com-
`plex Regional Pain Syndrome”, Anesthesiology, 113(3):713-25
`(2010).
`Brunner, Florian et al., “Biphosphonates for the therapy of complex
`regional pain syndrome 17Systematic review”, European Journal of
`Pain, 13:17-21 (2009).
`Cantatore FP, Acquista CA, Pipitone V. Evaluation of bone turnover
`and osteoclastic cytokines in early rheumatoid arthritis treated with
`alendronate. J Rheumatol 1999; 26: 2318-2323.
`Cecchini, Marco G. et al., “Bisphosphonates In Vitro Specifically
`Inhibit, Amound the Hematopoietic Series, the Development of the
`Mouse Mononuclear Phagocyte Lineage”, Journal of Bone and Min-
`eral Research, 5 (10):1019-1027 (1990).
`Chandler, Labeling of unit dose packages of drugs, Department of
`Pharmacy Policy, University of Kentucky Hospital, Chandler Medi-
`cal Center, policy No. PH-04-06, 2009 (in co-pending U.S. Appl. No.
`13/894,244).
`Chauvineau et al. “What is the place of biphosphonates in the treat-
`ment of Complex Regional Pain Syndrome I?” Annales de readapta-
`tion de medecine physique 48 (2005) 150-157.
`Classification of Chronic Pain. Descriptions of Chronic Pain Syn-
`dromes and Definitions of Pain Terms. Second Edition.
`Commission Regulation (EC) No. 847/2000, Official Journal of the
`European Communities, (2000).
`
`OTHER PUBLICATIONS
`L. S. Appl. \Io. 14/540,333, filedNov. 13, 2014 First\IamedInventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L. S. Appl. \Io. 14/604, 524, filed Jan. 23, 2015 First\Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L. S. Appl. \Io. 14/605, 822, filed Jan. 26, 2015 First\Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L. S. Appl. \Io. 14/607,947, filed Jan. 28, 2015 First\Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L. S. Appl. \Io. 14/607,985, filed Jan. 28, 2015 First\Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L. S. Appl. \I0. 13/894 244, filed VIay 14, 2013 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L. S. Appl. \I0. 13/894 252, filed VIay 14, 2013 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S. Appl. \Io. 13/894,262, filed VIay 14, 2013 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S. Appl. \Io. 13/894,274, filed VIay 14, 2013 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S.Appl. \Io. 14/106,291, filed Dec. 13,2013 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S. Appl. \Io. 14/279, 196, filed VIay 15, 2014 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S. Appl. \Io. 14/279,206, filed \/Iay15,2014 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S. Appl. \Io. 14/279,213, filed \/Iay15,2014 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S. Appl. \Io. 14/279,222, filed \/Iay15,2014 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S. Appl. \Io. 14/279,226, filed \/Iay15,2014 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S. Appl. \Io. 14/279,229, filed \/Iay15,2014 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S. Appl. \Io. 14/279,232, filed \/Iay15,2014 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S. Appl. \Io. 14/279,241, filed \/Iay15,2014 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S. Appl. \Io. 14/279,236, filed \/Iay15,2014 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S. Appl. \Io. 14/336,642, filed Jul. 21, 2014 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S.Appl. \Io. 14/456,939, filedAug. 11,2014 First\Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S.Appl.\Io. 14/457,659, filedAug. 12,2014 First\Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`L .S.Appl. \Io. 14/625,457, filed Feb. 18,2015 First \Iamed Inventor:
`LLC.
`Herriot Tabuteau Assignee: Antecip Bioventures II
`
`
`
`
`
`
`
`
`
`
`Page 2
`
`Page 2
`
`

`

`US 9,283,239 B2
`
`Page 3
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Committee for Orphan Medicinal Products (COMP) meeting report
`on the review ofapplications for orphan designation, European Medi-
`cines Agency, Sep. 2013.
`Complex regional pain syndrome. NHS choices Feb. 27, 2012.
`Complex Regional Pain Syndrome: Treatment Guidelines, Jun. 2006.
`Reflex Sympathetic Dystrophy Syndrome Association. Edited by R.
`Norman Harden.
`Conte, et al., The Oncologist 2004:9(Supp 4):28-37.
`Cremers, Serge C.L.M. et al., "Pharmacokinetics/Pharmacodynam-
`ics of Bisphosphonates”, Clin Pharmacokinet, 44 (6):551-570
`(2005).
`CRPS: Biphosphonateshave yet to prove their usefulness. Douleurs
`EvaluationiDiagnosticiTraitement (2009) 10, 214-217.
`Cullen et al., MER-101: A bioavailability study of various GIPET
`formulations in beagle dogs with intraduodenal cannulae. Poster
`Presentation, Nov. 2007.
`De Castro et al., Zoledronic acid to treat complex regional pain
`syndrome type I in adult (case report). Rev. Dor. Sao Paulo, 2011,
`12(1): 71-73.
`de Mos M, de Bruijn AGJ, Huygen FJPM, Dieleman JP, Stricker
`BHC, Sturkenboom MCJM. The incidence of complex regional pain
`syndrome: A population based study. Pain 2007; 129: 12-20.
`de Mos M, Huygen FJPM, van der Hoeven-Borgman M, Dieleman
`JP, Stricker BHC, Sturkenboom MCJM. Outcome of the complex
`regional pain syndrome. Clin J Pain 2009; 25: 590-597.
`Del Valle et a1. “Spinal cord histopathological alterations in a patient
`with longstanding complex regional pain syndrome.” Brain, Behav-
`ior and Immunity 23 (2009) 85-91.
`Dielissen et a1. “Amputation for Reflex Sympathetic Dystrophy.” Jo
`Bone Joint Surg 1995:77-B: 270-3.
`Drugs Orange Book Preface. Food and Drug Administration Center
`for Drug Evaluation and Research, 32nd Edition, accessed Mar. 6,
`2014.
`Drummond et al. “Reflex Sympathetic Dsytrophy: The Significance
`of Differing Plasma Catecholamine Concentrations in Affected and
`Unaffected Limbs.” Brain (1991), 2025-2036.
`E.U. Summary of product characteristics for Zometa and Aclasta
`(zoledronic acid).
`English, A life of pain: woman chooses amputation to deal with
`painful disorder. Http://www.katu.com/news/loca.A-life-of—pain-
`woman-chooses amputation-to-deal with .
`.
`. Nov. 18, 2013.
`EU Product Label for Zometa, accessed 2013.
`Fay A, Abinun M. Current management of hereditary angio-oedema
`(C’l esterase inhibitor deficiency). J Clin Pathol 2002; 55: 266-270.
`FDA Approved medication GuideiReclast (zoledronic acid) inj ec-
`tion, Aug. 2011.
`FDA Commissioner Margaret A. Hamburg Statement on Prescription
`Opioid Abuse
`(Apr.
`3,
`2014),
`available
`at: www.fda.gov/
`NewsEvents/Newsroom/PressAnnouncements/ucm3915 90 .htm.
`FDA Severe Pain with Osteoporosis drugs, Mar. 2008, FDA patient
`safety news: Show #73.
`Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in
`patients with complex regional pain syndrome: A double-blind pla-
`cebo-controlled trial oftopical ketamine. Pain 2009; 146: 18-25.
`Forouzanfar T, Koke AJ, van Kleef M, Weber WE. Treatment of
`complex regional pain syndrome type I. Eur J Pain 2002; 6: 105-122.
`Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate
`on chronic back pain due to osteoporotic vertebral fractures. Olin
`Rheumatol 1999;718: 266-267.
`Garth T. Whiteside et al., DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-
`1-phenyl-1 ,3,8-triazaspiro[4.5]dec-3 -yl]-acetic Acid), a Novel, Sys-
`temically Available, and Peripherally Restricted Mu Opioid Agonist
`with Antihyperalgesic Activity: II. In Vivo D Pharmacological Char-
`acterization in the Rat, 310 J. Pharmacol. & Exp. Ther. 793 (2004)).
`Geertzen JH, Dijkstra PU, van Sonderen EL, Groothoff JW, ten Duis
`HJ, Eisma WH. Relationship between impairments, disability and
`handicap in reflex sympathetic dystrophy patients: a long-term fol-
`low-up study. Clin Rehabil 1998; 12:402-412.
`
`Page 3
`
`Giles, Risedronate not an Effective Diesease Modifier in Knee
`Osteoarthritis. Arthritis News (website) 2006. Accessed at http://
`www.hopkinsarthritis.org/arthritis-news/risedronate-not-an-effec-
`tive-disease-modifier-in-knee-osteoarthritis.
`Goebel A, Barker CH, Turner-Stokes L et a1. Complex regional pain
`syndrome in adults: UK guidelines for diagnosis, referral and man-
`agement in primary and secondary care. London: RCP, 2012.
`Goebel A, Leite MI, Yang L, Deacon R, Cendan CM, Fox-Lewis A,
`Vincent A. The passive transfer of immunoglobulin G serum anti-
`bodies from patients with longstanding Complex Regional Pain Syn-
`drome. Eur J Pain 2011; 15: 504.e1-504.e6.
`Goebel A. Complex regional pain syndrome in adults. Rheumatology
`(Oxford) 2011; 50: 1739-1750.
`Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: a
`highly potent inhibitor of bone resorption. Drug Dev Res 2002; 55:
`210-224.
`Guideline on the format and content ofapplications for designation as
`orphan medicinal products and on the transfer of designations from
`one sponsor to another, Jul. 9, 2007. ENTIU6283/00 Rev 3.
`Guo et al., Substance P signaling contributes to the vascular and
`nociceptive abnormalities observed in a tibial fracture rat model of
`complex regional pain syndrome type I. Pain 108 (2004) 95-107.
`Halvorson KG, Kubota K, Sevcik MA, Lindsay TH, Sotillo JE,
`Ghilardi JR, Rosol TJ, Boustany L, Shelton DL, Mantyh PW. A
`blocking antibody to nerve growth factor attenuates skeletal pain
`induced by prostate tumor cells growing in bone. Cancer Res 2005;
`65: 9426-9435.
`Hendren et al., A review of the differences between normal and
`osteoarthrisis articular cartilage in human knee and ankle joints, The
`Foot, vol. 19, Issue 3, Sep. 2009, pp. 171-176.
`Henry McQuay, Opioids in pain management, 353 Lancet 2229,
`Abstract and 2229 (1999).
`Henson P, Bruehl S. Complex regional pain syndrome: state ofthe art
`update. Curr Treat Options Cardiovasc Med 2010; 12: 156-167.
`http://cancerguide.org/drugdosinghtml, Page Created: 2000,
`Updated: Sep. 22, 2000.
`Huygen FJ, De Bruijn AG, De Bruin MT, Groeneweg JG, Klein J,
`Zijistra FJ. Evidence for local inflammation in complex regional pain
`syndrome type 1. Mediators Inflamm 2002; 11:47-51.
`ICD-10-CM Tabular List of Diseases and Injuries 2012 p. 259-
`261,269-270. Source: The. National Center for Health Statistics
`(NCHS), Centers for Disease Control and Prevention.
`Kemler MA, Barendse GA, van KleefM, de Vet HC, Rij ks CP, Furnee
`CA, van den Wildenberg FA. Spinal cord stimulation in patients with
`chronic reflex sympathetic dystropy. N Engl J Med 2000; 343:618-
`624.
`Kemler MA, de Vet HC, Barendse GA, van den Wildenberg FA, van
`Kleef M. Spinal cord stimulation for chronic reflex sympathetic
`dystrophy-five-year follow-up. N Engl J Med 2006; 354: 2394-2396.
`Kemler MA, van de Vusse AC, van den Berg-Ioonen EM, Barendse
`GA, van Kleef M, Weber WE. HLA-001 associated with reflex sym-
`pathetic dystrophy. Neurology 1999; 53:1350-1351.
`Kim et al, Analgesic effects of the non-nitrogen-containing
`bisphosphonates etidronate and clodronate,
`independent of anti-
`resorptive effects on bone, European Journal of Pharmacology, vol.
`699, Issues 1-3, 15, Jan 2013, pp. 14-22 (Available online: Nov. 28,
`2012).
`Kingery et al., A substance P receptor (NK1) antagonist can reverse
`vascular and nociceptive abnormalities in a rat model of complex
`regional pain syndrome type II. Pain 104 (2003) 75-84.
`Kirveskari E, Vartiainen NV, Gockel M, Forss N. Motor cortex dys-
`function in complex regional pain syndrome. Clin Neurophysiol
`2010; 121: 1085-1091.
`Kohr D, Tschernatsch M, Schmitz K, Singh P, Kaps M, Schafer KH,
`Diener M, Mathies J, Matz 0, Kummer W, Maihofner C, FritzT,
`Birklein F, Blaes F. Autoantibodies in complex regional pain syn-
`drome bind to a differentiation-dependent neuronal
`surface
`autoantigen. Pain. 2009; 143: 246-251.
`Koman LA, Poehling GG, Smith BP, Smith TL, Chloros G. Chapter
`594Complex Regional Pain Syndrome. Green’s Operative Hand
`Surgery, 6th ed.: Churchill Livingstone, 2010.
`
`last
`
`Page 3
`
`

`

`US 9,283,239 B2
`Page 4
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Kopterides P, Pikazis D, Koufos C. Successful treatment of SAPHO
`syndrome with zoledronic acid. Arthritis Rheum 2004; 50: 2970-
`2973.
`Kramer HH, Eberle T, Uceyler N, Wagner I, Klonschinsky T, Muller
`LP, Sommer C, Birklein F. TNF-alpha in CRPS and ‘normal’ trauma-
`significant differences between tissue and serum. Pain 2011; 152:
`285-290.
`Kretzchmar A, Wiegel T, Al-Batran S, Hinrichs HF, Kindler M, Steck
`T, Illiger HJ, Heinemann V, Schmidt K, Haus U, Kirner A, Ehninger
`G. Rapid and sustained influence of intravenous zoledronic acid on
`course of pain and analgesics consumption in patients with cancer
`with bone metastases: A multicenter open-label study over 1 year.
`Supportive Cancer Therapy 2007; 4: 203 -210.
`Laslett, Extended report: Zoledronic acid reduces knee pain and bone
`marrow lesions over 1 year: a randomized controlled trial. Ann.
`Rheum. Dis. 2012, 71: 1322-1328.
`Leis et al. “Facilitated neurogenic inflammation in unaffected limbs
`of patients with complex regional pain syndrome.” Neuroscience
`Letters 359 (2004) 163-166.
`Leitha et al. “Pattern recognition in five-phase bone scintigraphy:
`diagnostic patterns of reflex sympathetic dystrophy in adults.” Euro-
`pean Journal ofNuclear Medicine vol. 23, No. 3, Mar. 1996.
`Leonard et al., MER-101 Tablets: A pilot bioavailability study of a
`novel oral formulation of zoledronic acid. Poster Presentation, Oct.
`2007.
`Leonard et al., Safety Profile of Zoledronic acid in a novel oral
`formulation. Poster Presentation, Nov. 2009.
`Leonard et al., Studies of bioavailability and food effects of MER-
`101 Zoledronic Acid Tablets in Postmenopausal Women. Poster Pre-
`sentation, Oct. 2009.
`Lewis et al. “Body perception disturbance: A contribution to pain in
`complex regional pain syndrome (CRPS).” Pain 133 (2007) 111-119.
`Maihofner et al. “Cortical reorganization during recovery from com-
`plex regional pain syndrome.” Neurology 2004; 63:693 -701.
`Maihofner et al. “Patterns of cortical reorganization in complex
`regional pain syndrome.” Neurology 2003; 61:1707-1715.
`Mailis-Gagnon et al. “Syrnpathectomy for neuropathic pain.”
`Cochrane Database of Systematic Reviews 2002,
`Issue 1. Art
`CD002918, 2009.
`Maksymowych et al. “A Six-Month Randomized, Controlled,
`Double-Blind, Dose-Response Comparison
`of
`Intravenous
`Pamidronate (60mg Versus 10mg) in the Treatment of Nonsteroidal
`Antiinflammatory Drug-Refractory Ankylo sing Spondylitis.” Arthri-
`tis & Rheumatism, vol. 46, No. 3, Mar. 2002, pp. 766-773.
`VIanicourt et al., Role of alendronate in therapy for postraumatic
`complex regional pain syndrome type 1 of the lower extremity
`arthirits rheum 2004.50:3690-3697.
`VIarinus et al. “Clinical features and pathophysiology of complex
`regional pain syndrome.” Neurology vol. 10, Jul. 2011.
`VIcHugh et al., MER-101-03, A multi center, phase II study to com-
`pare MER-101 20mg tablets to intravenous Zometa 4mg in prostate
`cancer patients. Poster Presentation, May 2009.
`VIerskey H, Bogduk N. Classification ofchronic pain: descriptions of
`chronic pain syndromes and definitions ofpain terms, 2nd ed. Seattle,
`WA: IASP Press, 1994 p. 40-43.
`VIos et al. “Medical history and the onset of complex regional pain
`syndrome (CRPS).” Pain 139 (2009) 458-466.
`VIos et al. “Outcome of the Complex Regional Pain Syndrome.” Clin
`J Pain, vol. 25, No. 7, Sep. 2009.
`VIos et al. “The association between ACE inhibitors and the complex
`regional pain syndrome: Suggestions for a neuro-inflammatory
`pathogenesis of CRPS.” Pain 142 (2009) 218-224.
`VIos et al. “The incidence of complex regional pain syndrome: A
`population-based study.”Pain 129 (2007) 12-20.
`\Iagae et al., Acidic microenvironment created by osteoclasts causes
`bone pain associated with tumor colonization. J. Bone Miner. Metab.
`(2007) 25: 99-104.
`\Iagae et al., Osteoclasts play a part in pain due to the inflammation
`adjacent to bone. Bone 39 (2006) 1107-1115.
`
`
`
`Page 4
`
`Nagakura et al., Allodynia and hyperalgesia in adjuvant-induced
`arthritic rats: time course of progression and efficacy of analgesics.
`The Journal of Pharmacology and Experimental Therapeutics 306:
`490-497, 2003.
`Nath et al. “Reflex Sympathetic Dystrophy.” Hand Surgery Update 1.
`vol. 23, No. 3, Jul. 1996.
`National Health Service, United Kingdom. Complex regional pain
`syndrome. NHS Choices, www.nhs.uk. Last reviewed May 23, 2012.
`Accessed Jul. 27, 2012.
`Transaction History page of related U.S. Appl. No. 13/894,244, filed
`Oct. 2013.
`Transaction History page ofrelated U.S. Appl. No. 13/894,252, filed
`Oct. 2013.
`Transaction History page of related U.S. Appl. No. 13/894,262, filed
`Oct. 2013.
`Turner-Stokes, Lynne et al., “Complex regional pain syndrome in
`adults: concise guidance”, Clinical Medicine, 11 (6): 596-600 (201 1).
`US Product Label for Zometa, revised 2012, Prescribing info.
`US Product Label for Zometa, revised Sep. 2013, FDA Prescribing
`Information for Zometa (zoledronic acid) injection.
`Van de Beek, Willem-Johan et al., “Susceptibility loci for complex
`regional pain syndrome”, Pain® 103:93-97 (2003).
`Van de Vusse, Anton C. et al., “Randomised controlled trial of
`gabapentin
`in Complex Regional Pain Syndrome
`type
`I
`[ISRCTN84121379]”, BMC Neurology, 4: 13: 1-9(2004).
`Van der Laan, Lijckle MD, et al., “Severe Complications of Reflex
`Sympathetic Dystrophy:
`Infection, Ulcers, Chronic Edema,
`Dystonia, and Myoclonus”, Arch Phys Med Rehabil, 79:424-429
`(1998).
`Van der Laan, Lycke, MD et al., “Reflex Sympathetic Dystrophy”,
`Hand Clinics, 13(3):373-385 (1997).
`Van Offel, J.F. et al., “Influence of cyclic intravenous pamidronate on
`proinflammatory monocytic cytokine profiles and bone density in
`rheumatoid arthritis treated with low dose prednisolone and
`methrotrexate”, Clinical and Experimental Rheumatology, 19: 13 -20
`(2001).
`Varenna et al., Intravenous clodronate in the treatment of reflex
`sympathetic dystrophy syndrome. A randomized, double blind, pla-
`cebo controlled study. J Rheumatol 2000: 27: 1477-1483.
`Varenna, Massimo et al., “Treatment of complex regional pain syn-
`drome type I with neridronate: a randomized, double-blind, placebo-
`controlled study”, Rheumatology, 1-9 (2012).
`Veldman, Peter HJM et al., “Signs and symptoms of reflex sympa-
`thetic dystrophy: prospective study of 829 patients”, The Lancet,
`342: 1012-1016 (1993).
`Walker et al., Disease modifyng and anti-nociceptive effects of the
`bispho sphonate, zoledronic acid in a model ofbone cancer pain. Pain
`100 (2002) 219-229.
`Wasner, Gunnar et al., “Traumatic Neuralgias%omplex Regional
`Pain Syndromes (Reflex Sympathetic Dystrophy and Causalgia):
`Clinical Characteristics,
`Pathophysiologic Mechanisms
`and
`Therapy”, Neurologic Clinics, 16 (4):851-868, (1998).
`Wasner, Gunnar et a1 ., “Vascular Abnormalities in Acute Reflex Sym-
`pathetic Dystrophy (CRPS I)”, Arch Neurol, 56:613-620 (1999).
`Weiss et al., Biodistribution and Plasma Protein Binding of
`Zoledronic Acid, Drug Metabolism and Disposition, vol. 36, No. 10,
`pp. 2043-2049, 2008.
`Yanow, Jennifer et al., “Complex Regional Pain Syndrome (CRPS/
`RSD) and Neuropathic Pain: Role ofIntravenous Bispho sphonates as
`Analgesics”, TheScientificWorld Journal, 8:229-236 (2008).
`Zaspel
`et
`al., Treatment of early stage CRPS Igcortisone
`(methylprednisolone) versus bisphosphonate (zoledronic acid). Ger-
`man Congress of Orthopedics and Traumatology. 7 1 st Annual Meet-
`ing of the German Society of Trauma Surgery, 93rd Meeting of the
`German Society for Orthopedics and Orthopedic Surgery, 48th Meet-
`ing of the Professional Association of Specialists in Orthopedics.
`Berlin, Oct. 24-27, 2007. German Medical Science GMS Publishing
`House; 2007.
`Zheng, Jack 2009, Formulation and Analytical development for low
`dose oral drug products, by John Wiley and Sons, Inc.
`Zoledronate Disodium: Treatment ofTumor-Induced Hypercalcemia
`Angiogenesis Inhibitor, Drugs of the Future 2000, 25(3) 259-268.
`Zometa FDA Pharmacology Review, part 1, accessed 2013.
`
`Page 4
`
`

`

`US 9,283,239 B2
`Page 5
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`than
`
`Zometa FDA Pharmacology Review, part 2, accessed 2013.
`Zometa FDA Pharmacology Review, part 3, accessed 2013.
`Zometa FDA Pharmacology Review, part 4, accessed 2013.
`Zometa FDA Pharmacology Review, part 5, accessed 2013.
`Zometa Label, Revised. Mar. 2012, Novartis Pharma Stein AG.
`Zyluk, A., “The Natural History of Post-Traumatic Reflex Sympa-
`thetic Dystrophy”, Journal of Hand Surgery (British and European
`Volume), 23B: 1:20-23 (1998).
`Olmsted County, Minnesota. Profile 0 General Demographic Char-
`acteristics: 2000. Source: US. Census Bureau, Census 2000 ' Sum-
`mary File 1, Matrices P1, P3, P4, P8, P9, P12, P13, P17, P18, P19,
`P20, P23, P27, P28, P33, PCT5,PCT8, PCT11, PCT15, H1, H3, H4,
`H5, H11, and H12.
`Opinion of the Committee for Orphan Medicinal Products on orphan
`medicinal product designation, European Medicines Agency, Sep.
`2013, pp. 1-3.
`Opree et al. “Involvement of the Proinflammatory Cytokines Tumor
`Necrosis Factor-a, IL-lB, and IL-6 But Not IL-8 in the Development
`of Heat Hyperalgesia: Effects on Heat Evoked Calcitonin Gene-
`Related Peptide Release
`from Rat Skin.” The
`Journal of
`Neuroscience, Aug. 15, 2000, 20(16):6289-6293.
`Orange Book: Active Ingredient Search. FDNCenter for Drug Evalu-
`ation and Research, Updated Feb. 28, 2014.
`Orazol(R): Novel approach to adjuvant therapy for improving out-
`comes in breast cancer. Merrion Pharmaceuticals, accessed 2013.
`Orcel “Response.” Joint Bone Spine 2002; 69; 522-2.
`Orcel et
`a1. “Bisphosphonates
`in bone diseases other
`osteoporosis.” Joint Bone Spine 2002; 69; 19-27.
`Pankaj et al. “Diagnosis of post-traumatic complex regional pain
`syndrome of the hand: current role of sympathetic skin response and
`three-phase bone schintigraphy.” Journal of Orthopaedic Surgery
`2006;14(3):284-90.
`Pennanen et al. “Effect of Liposomal and Free Bisphosphonates on
`the IL-lB, IL-6 and TNFa Secretion from RAW 264 Cells in Vitro.”
`Pharmaceutical Research, vol. 12, No. 6, 1995.
`Perez et a1. “Evidence based guideline for complex regional pain
`syndrome type 1.” BMC Neurology 2010, 10:20.
`Raj “Treatment of Fibrous Dysplasia with Zoledronic Acid Infusion
`Case Report, Review of Literature and Future Prospectives.”WebMD
`Central, ISSN 2046-1690, Published Nov. 22, 2010.
`Raja et a1. Complex Regional Pain Syndrome I (Reflex Sympathetic
`Dystrophy).Anesthesiology 2002; 96: 1254-60.
`Reclast Label, Revised: Aug. 2011, Novartis Pharma Stein AG.
`Reclast Medication Guide. Aug. 2011.
`Recommendation on elements required to support the medical plau-
`sibility and the assumption of significant benefit for an orphan des-
`ignation. EMNCOMP/15893/2009. Mar. 2, 2010.
`Reid et al. “Comparison of a Single Infusion ofZoledronic Acid with
`Risedronate for Paget’s Disease.” N Engl J Med 353:9, Sep. 1, 2005.
`Reid et al., Intravenous Zoledronic Acid in Postmenopausal Women
`with Low Bone Mineral Density. N. Engl. J. Med., vol. 346, No. 9,
`Feb. 2002.
`Rho et al. “Complex Regional Pain Syndrome.” May Clin Proc. 2002;
`77: 174-180.
`Ringe “Development of clinical utility of zoledronic acid and patient
`consideration in the treatment of osteoporosis.” Patient Preference
`and Adherence 2010:4 231-245.
`Ringe et al., A review of bone pain relief with ibandronate and other
`bisphosphonates in disorders of increased bone turnover. Clin. Exp.
`Rheumatol. 2007; 25: 766-774.
`Ripamonti et a1. “Decreases in pain at rest and movement-related pain
`during zoledronic acid treatment in patients with bone metastases due
`to breast or pro state cancer: a pilot study.” Support Care Center
`(2007) 15:1177-1184.
`Robinson et al., Efficacy of pamidronate in complex regional pain
`syndrome type I. Pain Med 2004; 5:276-280.
`Rooij et al. “Familial occurrence of complex regional pain syn-
`drome.” Eur J Pain 13 (2009) 171-177.
`
`Page 5
`
`Rooij et al. “HLA-B62 and HLA-DQ8 are associated with Complex
`Regional Pain Syndrome with fixed dystonia.” Pain 145 (2009)
`82-85.
`Rousselle et al. “Osteoclastic Acidifaction Pathways During Bone
`Resorption.” Bone vol. 30, No. 4, Apr. 2002: 533-540.
`Sandroni, Paola et al., “Complex regional pain syndrome type I:
`incidence and prevalence in Olmsted county, a population-based
`study”, Pain® 103:199-207, (2003).
`Sansoni, Paolo et al., “Inhibition ofAntigen-Presenting Cell Function
`by Alendronate In Vitro”, Journal of Bone and Mineral Research,
`10(11):1719-1725 (1995).
`Schinkel, Christian MD, et al., “Inflammatory Mediators are Altered
`in the Acute Phase of Posttraumatic Complex Regional Pain Syn-
`drome”, Clin J. Pain, 22(3):235-239 (2006).
`Schott GO. Bisphosphonates for pain relief in reflex sympathetic
`dystrophy? Lancet1997g350: 1117.
`Schwartzman, Robert J. et al., “The Natural History of Complex
`Regional Pain Syndrome”, Clin J Pain, 25 (4):273-280 (2009).
`Schwartzman, Robert J., et al., “Outpatient intravenous ketamine for
`the treatment of complex regional pain syndrome: A double-blind
`placebo controlled study”, Pain® 147: 107-115 (2009).
`Schwenkreis, P. et al., “Bilateral Motor Cortex Disinhibition in Com-
`plex Regional Pain Syndrome (CRPS) Type I ofthe Hand”, American
`Academy of Neurology, 61:5 15-5 19 (2003).
`Scientific Discussion. EMEA 2005, pp. 1-24.
`Sebastian, Complex regional pain syndrome. Indian J. Past Surg.,
`44(2): 298-307 (2011).
`Seok, Hyun et al., “Treatment of Transient Osteoporosis of the Hip
`with Intravenous Zoledronate”, Ann Rehabil Med, 35:432-435
`(201 1).
`the effects of the
`Sevcik, Molly A. et al., “Bone cancer pain:
`bisphosphonate alendronate on pain, skeletal remodeling,
`tumor
`growth and tumor necrosis”, Pain® 111:169-180 (2004).
`Sharma, Amit et al., “A Web-Based Cross-Sectional Epidemiological
`Survey of Complex Regional Pain Syndrome”, Regional Anesthesia
`and Pain Medicine, 34(2): 1 10-115 (2009).
`Sharma, Amit et al., “Advances in treatment ofcomplex regional pain
`syndrome: recent
`insights on a perplexing disease”, Curr Opin
`Anaesthesiol, 19:566-572 (2006).
`Sigtermans, Marnix J. et al., “Ketamine produces effective and long-
`term pain relief in patients with Complex Regional Pain Syndrome
`Type I”, Pain® 145:304-311 (2009).
`Sommer, Claudia et al., “Recent findings on how proinflammatory
`cytokines cause pain: peripheral mechanisms in inflammatory and
`neuropathic hyperalgesia”, Neurosience Letters, 361:184-187
`(2004).
`Sorbera et al., Zoledronate Disodium, Drugs of the Future 2000,
`25(3):259-268.
`St. Sauver, Jennifer L. et al., “Use of a Medical Records Linkage
`System to Enumerate a Dydamic Population Over Time: The Roch-
`ester Epidemiology Project”, Am J. Epidemiol, 173(9):1059-1068
`(201 1).
`Stanton-Hicks, Michael et al., “Complex Regional Pain Syndromes:
`Guidelines for Therapy”, The Clinical Journal of Pain, 14:155-166
`(1998).
`Stevenson, P Helen et al., “Cytotoxic and Migration Inhibitory
`Effects of Bisphosphonates on Macrophages”, Calcif Tissue Int,
`38:227-233 (1986).
`Study: The Use of Zoledronic Acid to Complex Regional Pain Syn-
`drome (Aclasta) sponsored by University of Sao Paulo General Hos-
`pital. 2012. Clinical Trials.gov. Accessed on Apr. 5, 2013 at http://
`clinicaltrials.gov/ct2/show/NCT01788176.
`The University of Sheffield, Health & Economic impact of a new
`drug intervention for osteoporosis. http://www.sheffield.ac.uld
`humanmetabolism/researchandyou/zoledronicacid, accessed Jun.
`2014.
`Tran, De Q.H., MD et al., “Treatment of complex regional pain
`syndrome: a review of the evidenceiTraitement du syndrome de
`douleur regionale complexe: une revue des nonnees probantes”, Can
`J. Anesth/J. Can Anesth, 57:149-166 (2010).
`Harden RN, Bruehl S, Perez RS, Birklein F, Marinus J, Maihofner C,
`Lubenow T, Buvanendran A, Mackey S, Graciosa J, Mogilevski M,
`
`Page 5
`
`

`

`US 9,283,239 B2
`Page 6
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Ramsden C, Chont M, Vatine JJ. Validation of proposed diagnostic
`criteria (the “Budapest Criteria”) for Complex Regional Pain Syn-
`drome. Pain 2010; 150: 268-274.
`Guideline Complex Regional Pain Syndrome type I, (2006).
`Pennanen N, Lapinj oki S, Urtti A, Monkkonen J. Effect of liposomal
`and free bisphosphonates on the IL-1 beta, IL-6 and TNFalpha secre-
`tion from RAW 264 cells in vitro. Pharm Res 1995; 12: 916-922.
`Public summary of opinion on orphan designation. Zoledronic acid
`for the treatment of complex regional pain syndrome.European
`Medicines Agency, 2013.
`Ying Wang et al., CXCL10 Controls Inflammatory Pain via Opioid
`Peptide-Containing Macrophages in Electroacupuncture, PLOS
`One, Apr. 2014, vol. 9, Issue 4, e94696.
`Epstein et al., Update of Monthly Oral Bisphosphanate Therapy for
`the Treatment of Osteoporosis: Focus on Ibandronate 150 mg and
`Risedronate 150 mg, Current Medical Research and Opinion Journal,
`25(12): 2951-2960, 2009.
`Robinson et al, Efficacy of Pamidronate in Complex Regional Pain
`Syndrome Type I, American Academy of Pain Medicine 1526-2375,
`pp. 276-280, 2004.
`Rehman et a1, P36 Treatment of reflex sympathetic dystrophy with
`intravenous pamidronate, Abstracts from the Bone and Tooth Society
`Meeting, Apr. 1991, p. 116.
`Siminoski et al., Intravenous Pamidronate for Treatment of Reflex
`Sympathetic Dystrophy During Breast Feeding, Journal of Bone and
`Mineral Research vol. 15, No. 10, 2000.
`Kubalek et al., Treatment of reflex sympathetic dystrophy with
`pamidronate: 29 cases, Rheumatology 2001; 40:1394-1397.
`Maillefert et al., Treatment of refractory reflex sympathetic dystro-
`phy with pamidronate, letters to the editor 1995, Correspondence to:
`Dr J F Maillefe